Estetrol in Menopause: How It’s Different From Estradiol

If you've been following menopause news, you may have noticed growing interest in an estrogen called estetrol. It has now been approved as a menopause hormone therapy (MHT) in Europe under the brand name FYLREVY, and new clinical trial and regulatory data have brought it into much sharper focus.

Estetrol vs. estradiol: the short answer

If you're here for the quick comparison, here it is. Estradiol and estetrol are both estrogens that act on the same receptors, and both can reduce hot flashes. Estradiol is the estrogen we've used for decades. It comes as pills, patches, gels, and more, with well-established benefits for hot flashes and bone health. Estetrol is a different molecule that behaves differently in some tissues in laboratory studies, and it has only recently been approved for menopause in Europe.

The important catch is that the pivotal menopause trials compared estetrol with placebo, not estradiol. So we know that estetrol works for menopausal symptoms, but we don't yet know whether it is safer or more effective than estradiol. Its different laboratory effects are interesting, particularly when it comes to the liver and clotting-related markers, but whether those differences translate into fewer blood clots, breast cancers, or other serious health outcomes remains unknown.

The rest of this post walks through what we actually know.

Estetrol vs. estradiol: how they differ

Estetrol, often shortened to E4, is a naturally occurring estrogen produced by the fetal liver during pregnancy. That makes it different from estradiol, which is produced primarily by the ovaries during the reproductive years.

Like estradiol, estetrol activates estrogen receptors, but laboratory studies suggest it behaves differently in some tissues, including differences between signaling inside the cell nucleus and signaling at the cell membrane.

The finding that gets the most attention is its relatively limited effect on some liver-produced proteins and clotting-related lab measures when taken by mouth. That's encouraging, but a favorable lab marker isn't the same as a lower risk of an actual blood clot. These studies weren't designed to answer that. Route matters here, too. Estradiol delivered through a patch or gel avoids the liver's first-pass exposure, and we have no evidence that oral estetrol is safer than transdermal estradiol.

It helps to remember where estradiol stands. It's the estrogen we have the most experience with in menopause care. It works well for hot flashes and night sweats, has well-established benefits for preventing bone loss, and comes in several formulations and routes. We also have decades of clinical experience with what we know about its benefits, risks, and different ways of giving it.

The evidence for estetrol and bone health is at a much earlier stage. In a 12-week phase 2 trial, women taking estetrol had lower levels of CTX-1, a blood marker of bone breakdown, than women taking placebo. That's a signal worth following, but these were lab markers rather than bone density scans or fractures, and the analysis was exploratory. These findings do not establish that estetrol prevents fractures, and FYLREVY is approved for menopause symptoms, not osteoporosis prevention.

So when you put estetrol next to estradiol, the biggest difference right now isn't that one has been shown to be better. It's that we have decades of clinical experience with estradiol and a much newer evidence base for estetrol.

Estetrol and breast and uterine tissue

Another reason people are paying attention is how estetrol appears to behave in breast and uterine tissue. Laboratory and animal studies, along with limited early human research, suggest it may be less stimulating than estradiol in some breast tissue models. That's interesting, but it doesn't show that estetrol lowers breast cancer risk. Effects vary with the experimental model and dose, and we don't have the long-term outcome data to answer that question. The European product information lists known, past, or suspected breast cancer as a contraindication for FYLREVY.

The uterus is a different story. Estetrol is still an estrogen, so it stimulates the endometrium, and women who have a uterus and use systemic estetrol need a progestogen for protection. In the studies that supported approval in Europe, women with a uterus took estetrol with continuous progesterone, and bleeding and endometrial changes were carefully monitored.

In a one-year safety study, women with a uterus received estetrol 18.9 mg with daily progesterone 100 mg. Among 325 women with evaluable endometrial biopsies obtained at 12 months or early discontinuation, there was one case of hyperplasia without atypia and no cases of atypical hyperplasia or endometrial cancer. That's reassuring within the limits of the study, but it doesn't establish long-term endometrial safety.

Bleeding was common, though. About 62% of women reported bleeding or spotting during months 10 to 12, and the European product information lists thickening of the uterine lining and vaginal bleeding as very common adverse reactions with this regimen.

Thickening on ultrasound isn't the same finding as hyperplasia on biopsy, but taken together, the data show real endometrial stimulation. Unexpected bleeding should be discussed with your clinician, especially if it persists or begins after you have been on a stable regimen for some time.

Estetrol and the brain

Estrogen acts in the brain, including in areas involved in temperature regulation and sleep, which is one reason estrogen therapy can reduce hot flashes and, for some women, improve sleep. Because estetrol reduces hot flashes in clinical trials, we know it has a real effect on temperature regulation.

What we don't yet know is whether it offers any particular advantage for mood, "brain fog," or long-term cognitive health. Estradiol-based MHT isn't recommended to prevent dementia and isn't an approved treatment for depression. Estradiol can improve depressive symptoms in some women during perimenopause, but it's no substitute for appropriate assessment and treatment of a mood disorder. And when someone feels sharper or sleeps better after starting hormone therapy, some of that improvement may be indirect. So there's no reason yet to think of estetrol as a special "brain estrogen."

FYLREVY: the estetrol therapy approved in Europe

FYLREVY® is an oral estrogen-only therapy that received European Commission marketing authorization on March 26, 2026. It's approved for estrogen-deficiency symptoms in postmenopausal women who have had a hysterectomy and in women with a uterus who are at least 12 months beyond their last menstrual period. Women with a uterus must also receive a progestogen continuously. [EMA citation]

The approval rested largely on two pivotal phase 3 trials, E4COMFORT I and II, which together enrolled 2,576 postmenopausal women across their efficacy and safety parts. About 1,200 of them took part in the principal placebo-controlled efficacy studies, which tested two doses, 14.2 mg and 18.9 mg. In those studies, both doses significantly reduced the frequency of moderate to severe hot flashes by week 4, with benefits maintained through week 12. The higher dose also significantly reduced severity in both trials, while the lower dose did so in one trial but not the other. [EMA citation]

On the clot question, the European product information lists venous thromboembolism (blood clots in the legs or lungs) as an uncommon adverse reaction and contraindicates FYLREVY in women with a previous or current VTE. [EMA citation]

Is estetrol available in the U.S.?

FYLREVY is approved in the European Union, but its U.S. status is different. As of October 7, 2026, I haven't located an FDA approval for estetrol as a menopause treatment or an announced U.S. availability date. European approval doesn't automatically confer U.S. approval, so it would be premature to predict when American patients might have access.

Estetrol in birth control (Nextstellis)

If the name sounds familiar, it may be because estetrol is already FDA-approved in the birth control pill Nextstellis, which combines estetrol with drospirenone and was first approved in 2021. That means we already have several years of human experience with estetrol as a molecule, and studies suggest it has a different effect on some clotting-related lab measures than ethinyl estradiol, the estrogen traditionally used in many birth control pills.

The caveat is that Nextstellis is a combined hormonal contraceptive, not MHT. It's used in a younger population, follows a different dosing schedule for a different purpose, and carries a risk of blood clots like other combined hormonal contraceptives. [FDA citation] Its estetrol dose overlaps with the lower FYLREVY dose, but that doesn't make the products interchangeable, and the contraceptive studies can't tell us the long-term risks and benefits of estetrol as MHT.

What estetrol means for menopause care right now

For most women in the U.S., nothing changes. Estradiol remains an established, well-studied option for systemic MHT, with multiple formulations and routes to choose from, and there's no reason to delay effective treatment while waiting for estetrol.

I do think estetrol is good news for menopause care. It adds a different estrogen molecule to what we already have, now backed by clinical trials and approved in Europe. We don't yet know whether it will prove meaningfully better than estradiol or simply give clinicians and patients another option, and answering that will take more research and longer-term experience.

Good menopause treatment has always been a matter of matching therapy to your symptoms, health history, risk factors, and preferences. If estetrol reaches the U.S., the useful conversation with your clinician will be whether it offers you something your current options don't.